Teva lupus drug fails in clinical trial

Wed Sep 19, 2007 11:25am EDT
 
[-] Text [+]

NEW YORK, Sept 19 (Reuters) - Israel's Teva Pharmaceuticals Industries Ltd (TEVA.O) said on Wednesday that its experimental treatment for lupus failed to meet the goal of a mid-stage clinical trial.

The drug, edratide, administered by subcutaneous weekly injection, appeared to be safe and well-tolerated but failed to reduce lupus disease activity over a 26-week treatment period, Teva said.

Analysis of secondary goals of the 340-patient study was still ongoing, Teva said. The company said any further development plans for edratide will be determined once those analyses have been completed. (Reporting by Bill Berkrot)

 
Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better